Vasculitis & polymyalgia rheumatica
Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients
Authors' conclusion
Refractory CME associated with BD uveitis can be effectively treated either with ADA, IFX or TCZ. Furthermore, TCZ is effective in patients resistant to anti-TNF therapy.
Study context
- Population
- Patients with Behçet's disease (BD)-associated cystoid macular edema (CME) refractory to conventional and/or biological immunosuppressive drugs72 eyes with CME
- Participants
- 49 patients
- Exposure
- ADA vs infliximab (IFX) vs tocilizumab (TCZ)
- ADAn = 25
- IFXn = 15
- TCZn = 9
- Outcome
- Evolution of macular thickness
- Follow-up
- From baseline up to 4 years
Methodological detailsBiological therapy in monotherapy (n=8) or combined with conventional immunosuppressive drugs (n=41)
- Biological therapy in monotherapy (n=8) or combined with conventional immunosuppressive drugs (n=41)
Main finding
As reported in the abstract
Macular thickness
- Macular thickness progressively decreased in the 3 groups, with no signs of CME after 1 year of treatment
Observational data: associations, not effects.
Further findings
Best-corrected visual acuity (BCVA) and intraocular inflammation
- BCVA improvement and inflammatory intraocular remission achieved in all groups
Original publication
Anti-TNF vs tocilizumab in refractory uveitic cystoid macular edema due to Behcet's disease. Multicenter study of 49 patients. Semin Arthritis Rheum. Published 14 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →